MANY MINDEDAI-Driven Genetic Therapies Could Reduce Disease Burden by 2028
IEEE's 2030 Technology Megatrends Report forecasts that AI-driven genetic therapies could reduce disease burden by 2028 through widespread implementation. The report—developed by 166 experts from 38 countries across six continents—rates healthcare technologies as having the highest impact (4.93/5) among all sectors. It identifies genetic engineering and gene therapy as technologies that will be used therapeutically within two years of the report's release, with earlier disease diagnoses moving from laboratory to clinical practice within five years. AI serves as the unifying thread connecting 30 breakthrough technologies and five megatrends, including those targeting energy efficiency and healthcare diagnostics.
The report's predictions depend on computing infrastructure availability, energy sources, workforce adaptation, and policy decisions. While the 2028 timeline assumes broad adoption, the forecasts are probabilistic and subject to technical and market conditions. Implementation barriers include scaling AI systems for clinical use and ensuring equitable access to emerging therapies.
This shift could make critical disease interventions more accessible by accelerating diagnosis and treatment. For health, it means conditions currently requiring complex, expensive procedures might become detectable earlier and treatable through scalable genetic solutions. However, the reduction in disease burden will only materialize if global systems adapt to support the technology's rollout—particularly in regions with limited healthcare infrastructure.
What to watch: Computing capacity gaps, regulatory pathways for AI-assisted therapies, and whether the 2028 target remains achievable given current energy constraints and workforce readiness.
Source: IEEE Spectrum